Angiogenesis, protein and gene delivery

被引:14
作者
Azrin, M [1 ]
机构
[1] Univ Connecticut, Ctr Hlth, Div Cardiol, Farmington, CT 06030 USA
关键词
D O I
10.1093/bmb/59.1.211
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Advances in our understanding of angiogenesis and blood vessel growth have given rise to efforts to develop novel therapeutic approaches for patients with ischaemia who are not adequately treated with presently available therapies. Among the growth factors that play a role in blood vessel growth and development, vascular endothelial growth factors and fibroblast growth factors have been the most extensively studied. Various methods of delivery have been utilized to enhance localization and persistence, including methods for delivery of proteins as well as gene transfer techniques. Initial clinical trials have now been undertaken. Preliminary information on efficacy is beginning to become available, raising hopes, as well as questions about the future direction and potential success of therapeutic angiogenesis as a clinical approach to the treatment of ischaemia.
引用
收藏
页码:211 / 225
页数:15
相关论文
共 44 条
[11]  
Henry TD, 1999, CIRCULATION, V100, P476
[12]  
Henry Timothy D., 1999, Journal of the American College of Cardiology, V33, p384A
[13]   Arterial gene transfer of naked DNA for therapeutic angiogenesis: early clinical results [J].
Isner, JM .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 30 (1-3) :185-197
[14]   Clinical evidence of angiogenesis after arterial gene transfer of phVEGF(165) in patient with ischaemic limb [J].
Isner, JM ;
Pieczek, A ;
Schainfeld, R ;
Blair, R ;
Haley, L ;
Asahara, T ;
Rosenfield, K ;
Razvi, S ;
Walsh, E ;
Symes, JF .
LANCET, 1996, 348 (9024) :370-374
[15]   Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: Preliminary clinical results [J].
Isner, JM ;
Baumgartner, I ;
Rauh, G ;
Schainfeld, R ;
Blair, R ;
Manor, O ;
Razvi, S ;
Symes, JF .
JOURNAL OF VASCULAR SURGERY, 1998, 28 (06) :964-973
[16]   Delivery strategies to achieve therapeutic myocardial angiogenesis [J].
Kornowski, R ;
Fuchs, S ;
Leon, MB ;
Epstein, SE .
CIRCULATION, 2000, 101 (04) :454-458
[17]   Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open-label dose escalation study [J].
Laham, RJ ;
Chronos, NA ;
Pike, M ;
Leimbach, ME ;
Udelson, JE ;
Pearlman, JD ;
Pettigrew, RI ;
Whitehouse, MJ ;
Yoshizawa, C ;
Simons, M .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (07) :2132-2139
[18]   Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery - Results of a phase I randomized, double-blind, placebo-controlled trial [J].
Laham, RJ ;
Sellke, FW ;
Edelman, ER ;
Pearlman, JD ;
Ware, JA ;
Brown, DL ;
Gold, JP ;
Simons, M .
CIRCULATION, 1999, 100 (18) :1865-1871
[19]   Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty [J].
Laitinen, M ;
Hartikainen, J ;
Hiltunen, MO ;
Eränen, J ;
Kiviniemi, M ;
Närvänen, O ;
Mäkinen, K ;
Manninen, H ;
Syvänne, M ;
Martin, JF ;
Laakso, M ;
Ylä-Herttuala, S .
HUMAN GENE THERAPY, 2000, 11 (02) :263-270
[20]  
Lathi KG, 2001, ANESTH ANALG, V92, P19